


# FINANCIAL TEAR SHEET

## Corporate Profile

AveXis, Inc. is a clinical-stage gene therapy company, dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Our initial product candidate, AVXS-101, is our proprietary gene therapy product candidate currently in development for the treatment of spinal muscular atrophy, or SMA, Type 1, the leading genetic cause of infant mortality. The U.S. Food and Drug Administration, or FDA, has granted AVXS-101 Orphan Drug Designation for the treatment of all types of SMA and Breakthrough Therapy Designation, as well as Fast Track Designation for the treatment of SMA Type 1. In addition to developing AVXS-101 to treat SMA Type 1, we plan to develop AVXS-101 to treat additional SMA types and develop other novel treatments for rare neurological genetic diseases.

## Stock Information

AVXS (Common Stock)	
Exchange	NASDAQ GS (US Dollar)
Price	<b>\$217.83</b>
Change (%)	0.00 (0.00%)
Volume	222
52 Week High	\$217.94
52 Week Low	\$65.54
Market Cap	\$8,019,732,967
Rolling EPS	-12.34
PE Ratio	0
Shares Outstanding	36,816,476
Data as of 05/14/18 4:00 p.m. ET	



## Recent Headlines

05/03/18

[AveXis Reports First Quarter 2018 Financial and Operating Results](#)

05/01/18

[AveXis Provides Update on Proposed Acquisition by Novartis AG](#)

04/25/18

[AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3](#)

## Upcoming Events

There are currently no events scheduled.

## SEC Filings

Filing Date	Form
05/22/18	<a href="#">EFFECT</a>
05/17/18	<a href="#">SC 13D/A</a>
05/16/18	<a href="#">CT ORDER</a>
05/15/18	<a href="#">3</a>

## Primary IR Contact

Vice President, Investor Relations and Corporate Communications

Jim Goff

Phone: (650) 862-4134

E-mail: [jgoff@avexis.com](mailto:jgoff@avexis.com)

Data provided by Nasdaq. Minimum 15 minutes delayed.